Results from Cardiovascular Outcome Trials in Diabetes.
نویسندگان
چکیده
Los pacientes con diabetes mellitus tipo 2 (DM2) tienen un riesgo de enfermedad cardiovascular (ECV) elevado tanto por la hiperglucemia como por otros factores de riesgo vascular asociados y, además, un peor pronóstico ante los eventos cardiovasculares. La diabetes acentúa la gravedad de todas las fases de la aterosclerosis, su desarrollo y sus complicaciones. En los pacientes con diabetes existe un exceso de mortalidad atribuida a causas cardiovasculares frente a la población no diabética (HR: 2,32; IC 95%: 2,112,56) y el infarto de miocardio y el ictus explican el 80% de las muertes en los pacientes con DM2. En este contexto se ha estimado que los pacientes con diabetes tienen un riesgo de presentar un evento cardiovascular unos 15 años antes que los no diabéticos. Así, la intervención integral sobre los factores de riesgo de ECV en esta población es recomendada para mejorar el pronóstico. Un aspecto singular es la importancia del control de la glucemia en esta aproximación integral. Sin embargo, el efecto sobre el desarrollo y la progresión de la ECV de los fármacos antidiabéticos es, en la actualidad, insuficientemente conocido. En los años previos, una serie de ensayos clínicos (ADVANCE, ACCORD, VADT) han evaluado el efecto del control estricto de la
منابع مشابه
A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing the Safety of Dapagliflozin in Type 1 Diabetes Patients
Background and Purpose: The dapagliflozin’s safety profile in insulin-treated adult type-1 diabetes mellites (T1DM) patients remains poorly explored. Therefore, this systematic review and meta-analysis compared the risk of all-cause side effects, study discontinuation of participants due to side effects, urinary tract infection (UTI), diabetic ketoacidosis, and hypoglycemia between dapagliflozi...
متن کاملFollow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
This commentary analyzes the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which has reported the cardiovascular benefits of liraglutide. It places the results of this seminal trial in the context of the evolution of diabetes care, compares them with other recently published cardiovascular outcome trials, and suggests novel mechanisms to...
متن کاملCardiovascular outcome trials in type 2 diabetes: what have we learned from the past and present?
There is a wealth of epidemiological data which shows that type 2 diabetes significantly increase the risk of cardiovascular events. The evidence from earlier trials have demonstrated that improvement in glycated haemoglobin will reduce the risk of micro vascular disease but there is lack of robust evidence to suggest whether improvement in glycaemic control will have similar beneficial outcome...
متن کاملEffects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
Empagliflozin, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor, has shown a remarkable reduction in cardiovascular and all-cause mortality in patients with type 2 diabetes (T2D) and antecedents of cardiovascular disease in the EMPA-REG OUTCOME trial. This effect has been attributed to a hemodynamic rather than a metabolic effect, partly due to the osmotic/diuretic effect of empagliflozi...
متن کاملUpdates on cardiovascular outcome trials in diabetes
In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials...
متن کاملAssociation of the FDA Amendment Act with trial registration, publication, and outcome reporting
BACKGROUND Selective clinical trial publication and outcome reporting has the potential to bias the medical literature. The 2007 Food and Drug Administration (FDA) Amendment Act (FDAAA) mandated clinical trial registration and outcome reporting on ClinicalTrials.gov, a publicly accessible trial registry. METHODS Using publicly available data from ClinicalTrials.gov, FDA documents, and PubMed,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion
دوره 63 7 شماره
صفحات -
تاریخ انتشار 2016